Legal & General Group
AXSM icon

Legal & General Group’s Axsome Therapeutics AXSM Stock Holding History

Legal & General Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.97M Sell
29,398
-7,304
-20% -$1.26M ﹤0.01% 1512
2025
Q4 		$6.7M Sell
36,702
-1,083
-3% -$151K ﹤0.01% 1409
2025
Q3 		$4.59M Sell
37,785
-2,460
-6% -$277K ﹤0.01% 1626
2025
Q2 		$4.2M Buy
40,245
+4,136
+11% +$438K ﹤0.01% 1630
2025
Q1 		$4.21M Sell
36,109
-261
-0.7% -$29.7K ﹤0.01% 1606
2024
Q4 		$3.08M Buy
36,370
+2,107
+6% +$194K ﹤0.01% 1802
2024
Q3 		$3.08M Buy
34,263
+614
+2% +$53.6K ﹤0.01% 1797
2024
Q2 		$2.71M Buy
33,649
+782
+2% +$57.9K ﹤0.01% 1806
2024
Q1 		$2.62M Sell
32,867
-150
-0.5% -$12.6K ﹤0.01% 1810
2023
Q4 		$2.63M Sell
33,017
-883
-3% -$59K ﹤0.01% 1810
2023
Q3 		$2.37M Buy
33,900
+576
+2% +$43.1K ﹤0.01% 1817
2023
Q2 		$2.39M Buy
33,324
+2,676
+9% +$197K ﹤0.01% 1838
2023
Q1 		$1.89M Buy
30,648
+3,637
+13% +$239K ﹤0.01% 1900
2022
Q4 		$2.08M Buy
27,011
+250
+0.9% +$14.9K ﹤0.01% 1867
2022
Q3 		$1.19M Sell
26,761
-1,771
-6% -$88.5K ﹤0.01% 2094
2022
Q2 		$1.09M Buy
28,532
+5,987
+27% +$189K ﹤0.01% 2131
2022
Q1 		$933K Sell
22,545
-14
-0.1% -$434 ﹤0.01% 2249
2021
Q4 		$852K Buy
22,559
+60
+0.3% +$2.21K ﹤0.01% 2274
2021
Q3 		$741K Buy
22,499
+4,752
+27% +$185K ﹤0.01% 2319
2021
Q2 		$1.2M Sell
17,747
-166
-0.9% -$9.96K ﹤0.01% 2163
2021
Q1 		$1.01M Buy
17,913
+2,031
+13% +$143K ﹤0.01% 2190
2020
Q4 		$1.29M Sell
15,882
-82
-0.5% -$6.13K ﹤0.01% 2040
2020
Q3 		$1.14M Sell
15,964
-1,220
-7% -$95.1K ﹤0.01% 1986
2020
Q2 		$1.41M Buy
17,184
+189
+1% +$14.5K ﹤0.01% 1873
2020
Q1 		$1M Buy
16,995
+9,068
+114% +$739K ﹤0.01% 1850
2019
Q4 		$820K Buy
7,927
+2,691
+51% +$109K ﹤0.01% 2116
2019
Q3 		$106K Hold
5,236
– – ﹤0.01% 2500
2019
Q2 		$135K Buy
+5,236
New +$105K ﹤0.01% 2441
2017
Q2 		– Sell
-1,158
Closed -$5K – 3358
2017
Q1 		$5K Hold
1,158
– – ﹤0.01% 3237
2016
Q4 		$8K Buy
+1,158
New +$8.13K ﹤0.01% 3246

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group's AXSM Position: Q1 2026 in Review

Legal & General Group reduced its Axsome Therapeutics (AXSM) stake by 20% in Q1 2026, selling an estimated $1.26M and leaving 29,398 shares worth $4.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1512.

Legal & General Group first reported a position in AXSM in Q4 2016 and has held it in 30 quarters since. The position peaked at $6.7M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Legal & General Group held 29,398 shares of Axsome Therapeutics worth $4.97M as of Q1 2026.
  • Legal & General Group sold 7,304 Axsome Therapeutics shares in Q1 2026, an estimated $1.26M.
  • Axsome Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1512 holding.
  • Legal & General Group first reported a position in Axsome Therapeutics in Q4 2016 and has held it in 30 quarters since.
  • Legal & General Group's Axsome Therapeutics position peaked at $6.7M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.